Outcomes and Mutational Analysis of a Prospective Phase II Trial of Azacitidine in Patients with MDS and AML with Early Post-Transplant Relapse

Post-transplant relapse remains a major cause of treatment failure in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Understanding of the biology of relapse and response to azacitidine treatment remains limited.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Janghee Woo, Barry Storer, Bart Scott, H. Joachim Deeg Source Type: research